在动脉样硬化进展中阿尔特米西宁的新作用
Hamidreza Majidiani1, Maryam Musavi2, Amir Abbas Momtazi-Borojeni2
1Department of Basic Medical Sciences, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Phytotherapy research : PTR
|April 9, 2025
概括
艺术素是一种天然化合物,通过减少炎症,氧化应激和改善血管光滑肌肉细胞功能,在治疗动脉样硬化方面表现有前途. 需要进一步的临床试验来确认它在患者中的有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 自然产品 自然产品
背景情况:
- 阿尔特米西宁来自于Artemisia annua,是FDA批准的疟疾药物.
- 新兴研究突出显示了素在动脉样硬化中的潜在治疗作用.
- 在体内研究表明,素能够抑制动脉样硬化斑块的进展.
研究的目的:
- 审查关于阿美西宁对动脉样硬化斑块进展的抑制作用的证据.
- 阐明阿尔特米西宁在动脉样硬化中的作用的潜在机制.
- 探索阿尔特米西宁作为动脉样硬化治疗新型治疗剂的潜力.
主要方法:
- 审查现有的体内研究和机理学研究.
- 分析素对关键动脉样硬化风险因素的影响.
- 检查由艺术素调节的分子通路.
主要成果:
- 素调节高脂血症,炎症,氧化应激和血管光滑肌肉细胞 (VSMC) 功能.
- 阿特苏纳酸是一种衍生物,通过KFL2/NRF2/TCF7L2轴降低脂质水平和动脉沉积.
- 甲素通过抑制单细胞粘附,NLRP3炎症酶和NF-κB活性来缓解斑块炎症.
- 甲素通过PI3K/Akt/eNOS信号产生抗氧化作用,并抑制ROS介导的NF-κB.
- 素改善了动脉样硬化斑块中的VSMC功能.
结论:
- 甲素对动脉样硬化进展表现出多方面的抑制作用.
- 机制包括调节脂质代谢,炎症,氧化应激和VSMC功能.
- 素显示出作为动脉样硬化的一种新型治疗剂的潜力,需要进行临床试验.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
568
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
568
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
417
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
417
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
548
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
548
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
100
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
100
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
391
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
391